Truscreen Group Limited (ASX: TRU) - Share Price
- Current share price for TRU : $0.013
TruScreen Group Limited (TRU), an ASX-listed company, is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli. Its cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly personnel and supporting laboratory infrastructure.
TRU General Information +
| ASX Code | TRU |
| Website | http://www.truscreen.com |
| Industry/Sector | Health Care Equipment |
| Market Cap ($M) | 13 |
| TRU Share Price | $0.013 |
| Day High | $0.014 |
| Day Low | $0.013 |
| Last Close | $0.013 |
| TRU Share Price Movement | - ( No change ) |
Prices as at 16:36, 22 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Truscreen Group Limited (TRU) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| Interim | 17¢ | 100% | 15 Oct 2013 | 5 Nov 2013 | - | - | - |
| Final | 18¢ | 100% | 29 Apr 2013 | 17 May 2013 | - | - | - |
| Interim | 12¢ | 100% | 17 Oct 2012 | 8 Nov 2012 | - | - | - |
See all dividends from Truscreen Group Limited (TRU) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Truscreen Group Limited (TRU) price-sensitive announcements
TRU - Rights Issue Completes Substantially Oversubscribed
TruScreen Group Limited announced the successful completion of a substantially oversubscri
Truscreen Group Limited (TRU)
25 Jun 2026 | 11:48 AM
25 Jun 2026 | 11:48 AM
TRU - Milestone Markets Update
TruScreen Group Limited, a leader in AI-enabled cervical cancer screening, has released a
Truscreen Group Limited (TRU)
12 Jun 2026 | 7:30 AM
12 Jun 2026 | 7:30 AM
TRU - TruScreen Preliminary Final Results FY2026 Presentation
TruScreen Group Limited, an AI-enabled cervical cancer screening company, reported over NZ
Truscreen Group Limited (TRU)
29 May 2026 | 7:30 AM
29 May 2026 | 7:30 AM
TRU - TruScreen Preliminary Final Results FY2026
Truscreen Group Limited reported a 42% increase in product sales for FY2026, driven by an
Truscreen Group Limited (TRU)
29 May 2026 | 7:30 AM
29 May 2026 | 7:30 AM
Truscreen Group Limited (TRU) Recent ASX Announcements
TRU Financial Summary
| Year to Mar | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | -$1.88 | -$0.30 | -25.70% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$2.04 | -$0.40 | -18.60% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$1.88 | -$0.40 | -21.80% | 0.00 | 0.00 | 0.00% | 0.0% |
TRU Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| Cochlear Limited (COH) | $7,782M | 0.0171 | -0.1894 | 0.0615 | 19.8854 | 24.5320 | 23.1099 | 3.61% | 2.91% | 3.03% |
| Fisher & Paykel Healthcare Corporation Limited (FPH) | $19,510M | 0.1388 | 0.1362 | 0.1882 | 50.2344 | 44.2108 | 37.2088 | 1.31% | 1.40% | 1.58% |
| ResMed Inc. (RMD) | $16,745M | 0.3087 | 9.7669 | 0.0729 | 193.8790 | 18.0070 | 16.7828 | 1.19% | 1.25% | 1.31% |
| Truscreen Group Limited (TRU) | $13M | -0.2571 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
TRU Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 4.64 | 0.00 |
| Market | 0.31 | 12.80 | 1.12 | 0.58 |
| Sector | 0.69 | 20.50 | 1.54 | 1.88 |
TRU Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Anthony (Tony) Peng Ho | Executive Chairman, Executive Director | 4 Oct 2018 |
| Ms Christine Pears | Non-Executive Director | 11 Sep 2025 |
| Dr Dexter Cheung | Non-Executive Director | 1 Mar 2021 |
| Mr Reece O'Connel | Non-Executive Director | 3 Jun 2026 |
Truscreen Group Limited (TRU) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 27 Feb 2026 | HO, Anthony (Tony) | Buy | Indirect Shares | 500,000 | $0.018 | $9,121.000 |
| 20 Mar 2024 | CHEUNG, Dexter | Issued | Direct Shares | 167,777 | $0.020 | $3,356.000 |
| 20 Mar 2024 | HO, Anthony (Tony) | Issued | Indirect Shares | 2,223,333 | $0.020 | $44,467.000 |
See all changes in directors' interest & trades for Truscreen Group Limited (TRU) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
TRU Management
| Name | Position |
|---|---|
| Guy Adrian Robertson | Chief Financial Officer,Company Secretary |
| Dr Jerry Tan | General Manager Commercial |
| Martin Dillon | Interim CEO |
| Dr Carolina Velasquez | Medical Affairs and Training Manager |
| Usharani Raji | Technology and Production Manager |
TRU Calendar of Events
| Date | Event |
|---|---|
| 28 June 2027 | Report (Annual) |
| 28 May 2027 | Report (Prelim) |
| 27 November 2026 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
